September 8, 2021
After a comprehensive executive search that was completed in less than six weeks, The Chase Group is pleased to announce the placement of Dr. Molly Shea with the management team at Atsena Therapeutics. Dr. Shea brings well-rounded experience of 18+ years of drug development and regulatory science in industry and FDA in the Center for Drug Evaluation and Research.
The Chase Group welcomes the partnership with Atsena Therapeutics to aid in their organizational growth as they strive to overcome the hurdles presented by inherited retinal disease. Atsena is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. Founded by ocular gene therapy pioneers Dr. Shannon Boye and Sanford Boye of the University of Florida, Atsena is based in North Carolina’s Research Triangle, an environment rich in gene therapy expertise. The Chase Group never loses sight of how its services can profoundly impact the future success of an organization and appreciated the focused collaboration with Dr. Kenji Fujita, Chief Medical Officer, and the leadership team at Atsena. To learn how The Chase Group can identify high caliber talent for your team, please contact moira@chasegroup.com.
